{"schema_version":"1","generated_at":"2026-11-21T13:12:00.088Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gerald-miletello","json_url":"https://www.findmykol.com/kol/gerald-miletello/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gerald-miletello","name":"Gerald Miletello","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Baton Rouge","state":"LA","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Gerald Miletello is an Oncology physician. OpenAlex indexes 20 publications with 402 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":20,"cited_by_count":402,"h_index":7,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":76,"program_years":{"first":2021,"last":null},"rows_total":212,"shown":3,"withheld":209,"rows":[{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":379.75,"payment_count":14},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":330.07,"payment_count":16},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":303.21,"payment_count":14}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":33.1,"classes_total":11,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":31.7,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":11},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":0.6,"drugs":[{"name":"Letrozole","share_pct":56.3},{"name":"Anastrozole","share_pct":43.7}],"max_beneficiaries":39}]},{"area":"Metabolism & gastrointestinal","share_pct":29.4,"classes_total":5,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":23.8,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":19},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":5.2,"drugs":[{"name":"Palonosetron hcl","share_pct":70},{"name":"Ondansetron hydrochloride","share_pct":26.4},{"name":"Ondansetron Hcl","share_pct":2.9},{"name":"Ondansetron Odt","share_pct":0.7}],"max_beneficiaries":41}]},{"area":"Musculoskeletal","share_pct":23.2,"classes_total":1,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":23.2,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":27}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.7,"facility_pct":0.3},"source":"medicare"},"publications":{"total":20,"shown":5,"withheld":15,"matched_by":"OpenAlex author record","recent":[{"title":"A randomized trial of a multimodal lifestyle intervention in cancer survivors","year":2025,"journal":"Frontiers in Oncology","source_url":"https://doi.org/10.3389/fonc.2025.1682244","status":"verified"},{"title":"Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2","year":2021,"journal":"Journal of Investigative Medicine","source_url":"https://doi.org/10.1136/jim-2020-001650","status":"verified"},{"title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","year":2019,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1186/s40425-019-0522-3","status":"verified"},{"title":"Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry","year":2019,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1186/s40425-019-0567-3","status":"verified"},{"title":"Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM","year":2019,"status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":209,"publications":15}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}